Dr. John Cush RheumNow
5 years 3 months ago
"Arthritis Mutilans" - worse outcome to chronic inflammatory arthritis is due to 5 disorders:
1) RA
2) Psoriatic arthritis
3) Tophaceous gout
4) polyarticular JIA
5) Multicentric reticulohistiocytosis (Ive never seen this!!)
https://t.co/XYmBEW1F0R https://t.co/010QYkOO7E
Dr. John Cush RheumNow
5 years 3 months ago
Serious problem! Pulmonologists believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/vUyCxJP2Mh
Dr. John Cush RheumNow
5 years 3 months ago
Protective Effects of Colchicine in Non-Hospitalized COVID-19
A press release from the Montreal Heart Institute has announced that the COLCORONA clinical trial has provided evidence of the protective effect of colchicine.
Read more:
https://t.co/xW5SchMUeK https://t.co/tUoDTJKbVG
Dr. John Cush RheumNow
5 years 3 months ago
Psoriasis has greatest risk of MTX liver dz - a Danish Population study of PsO, PsA & RA pts taking MTX. Risk of liver Dz was most in PsO, followed by PsA, then RA. PsO had 1.6-3.4 fold risk (mild-severe) liver dz (vs RA). PsA was 1.3-1.6x higher)
https://t.co/pAo9KFr5fO
The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to at-risk rheumatoid arthritis patients. These findings are in addition to the thrombotic risks (added to the label), potential risks including blood
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Dr. John Cush RheumNow
5 years 3 months ago
1/3 of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
Read more:
https://t.co/K8zf1pE9jM https://t.co/eu2Byo6dx4
Dr. John Cush RheumNow
5 years 3 months ago
The ACR has a new position on patient safety and site of service for biologics— it strongly believes infusions should be given in a monitored health care setting with onsite supervision by a provider w/ training in biologic infusions.
https://t.co/NONozoIIq6 https://t.co/PQMvUZqnMW
Dr. John Cush RheumNow
5 years 3 months ago
A study of rheumatologists in Ontario, Canada has shown an increasing percentage of women in rheumatology; unfortunately they have lower salaries but see fewer patients than do their older, male colleagues.
Read more:
https://t.co/JM0345p8f1 https://t.co/y95LQ6lX5i
Dr. John Cush RheumNow
5 years 3 months ago
Download this week’s podcast titled “Good as I Ever Was”. You can find us on SoundCloud and wherever you download your podcasts.
https://t.co/hVMf8X5Dx3 https://t.co/uUDCXzO2eU
Dr. John Cush RheumNow
5 years 3 months ago
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate
https://t.co/J9wmcZr17D
Dr. John Cush RheumNow
5 years 3 months ago
How risky are family gatherings, birthday parties and informal social gatherings?
Read more…
https://t.co/jyGHakndUt https://t.co/7eps0EFVWy
Dr. John Cush RheumNow
5 years 3 months ago
Brand new RheumNow podcast up titled “As Good As I Ever Was”
Download now.
https://t.co/hVMf8X5Dx3 https://t.co/2R2kq7dwp5 https://t.co/5mahn4D46M
Dr. John Cush RheumNow
5 years 3 months ago
Therapeutic Drug Monitoring for Infliximab: Might it Actually Work?
https://t.co/Onl6cijKbb https://t.co/jnwx4ZZvhz
